Inventiva (IVA) Retained Earnings (2018 - 2025)
Inventiva (IVA) posted quarterly Retained Earnings of -$3.2 million for Q4 2025, down 174.58% year-over-year from $4.3 million in Q4 2024, and up 100.0% quarter-over-quarter from -$239.4 billion in Q2 2025.
Analysis
Inventiva (IVA) Retained Earnings (2018 - 2025) Analysis & Trends
Inventiva's Retained Earnings history runs 8 years deep, the most recent figure standing at -$3.2 million for Q4 2025.
- In Q4 2025, Retained Earnings fell 174.58% year-over-year to -$3.2 million; the TTM figure through Dec 2025 stood at -$3.2 million (down 174.58% YoY), while the FY2025 annual figure was -$3.2 million, down 174.58% from the prior year.
- Retained Earnings for Q4 2025 stood at -$3.2 million, up from -$239.4 billion in the prior quarter.
- The five-year high for Retained Earnings was -$190842.4 in Q4 2023, with the low at -$239.4 billion in Q2 2025.
- The 5-year median for Retained Earnings is -$18.7 million (2025), against an average of -$35.0 billion.
- Peak annual rise in Retained Earnings reached 174.58% in 2025, while the deepest fall reached 21839761.57% in 2025.
- Inventiva's Retained Earnings stood at -$30.7 billion in 2021, then slumped by 160.48% to -$79.9 billion in 2022, then surged by 100.0% to -$191517.3 in 2023, then tumbled by 507.62% to -$1.2 million in 2024, then sank by 174.58% to -$3.2 million in 2025.
- Business Quant data shows IVA's Retained Earnings at -$3.2 million in Q4 2025, -$239.4 billion in Q2 2025, and -$1.2 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Inventiva | 893.85 Mn | 893.85 Mn | - | -412.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -412.23 Mn |
| Jun 30, 2025 | -199.09 Mn |
| Dec 31, 2024 | -196.85 Mn |
| Jun 30, 2024 | -1.63 Mn |
| Dec 31, 2023 | -118.81 Mn |
| Dec 31, 2022 | -55.37 Mn |
| Jun 30, 2022 | -31.44 Mn |
| Dec 31, 2021 | -56.78 Mn |
| Jun 30, 2021 | -27.86 Mn |
| Mar 31, 2021 | -10.66 Mn |
| Dec 31, 2020 | -40.08 Mn |
| Dec 31, 2019 | -33.45 Mn |
| Dec 31, 2018 | -37.68 Mn |